Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

Avacta Group PLC LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura Bio Inc. (Boston, USA), and F2G Ltd (Manchester, UK), and is a senior advisor to Athyrium Capital Management LP (New York, USA) and Forbion Ventures (Naarden, Netherlands). Christina Coughlin, CEO of Avacta commented: "We are delighted to welcome Patrick to the Board of Directors of Avacta. His appointment adds considerable sector experience in Pharma partnering, financing, andoperations, having worked for a number of European and US companies, both private and listed. His extensive experience and expertise in building companies comes at a key time for Avacta as we advance our pipeline, based on our proprietary pre|CISION ® platform which brings unique potential advantages to cancer patients, and continue constructive partnership discussions across our asset portfolio." Patrick Vink, Deputy Chairman of Avacta, added: "I am excited to join the Board of Avacta at this important time for the company. Avacta's pre|CISION ® technology has the potential to change the way that the field thinks about cancer therapy. Upcoming data, includin...